Gastrointestinal Cancer-associated Fibroblasts: Revealing Their Changing Functions in the Tumor

^*Correspondence: Brandon Rodriguez, Department of Medical Genetics and Genomics, University of Melbourne, Parkville VIC 3010, Australia, Email:

Introduction

Gastrointestinal cancers constitute a significant global health burden, with Cancer-Associated Fibroblasts (CAFs) emerging as key players in shaping the tumor microenvironment. This article provides an in-depth exploration of the evolving functions of gastrointestinal CAFs, shedding light on their dynamic roles in cancer progression and therapeutic resistance. Through a comprehensive review of current literature and ongoing research, this article highlights the diverse functions of CAFs in different stages of gastrointestinal cancer, emphasizing their potential as therapeutic targets. The molecular mechanisms governing the changing functions of CAFs and their interactions with cancer cells are discussed, offering insights into novel strategies for precision medicine in gastrointestinal cancer treatment [1].

Gastrointestinal cancers, encompassing malignancies of the esophagus, stomach, liver, pancreas, and colorectum, represent a formidable challenge to global health. Amidst the intricate landscape of the tumor microenvironment, Cancer-Associated Fibroblasts (CAFs) have emerged as crucial players orchestrating various aspects of cancer progression. This article delves into the intricate roles of gastrointestinal CAFs, unraveling their changing functions in response to evolving tumor dynamics. Understanding the molecular mechanisms governing CAF behavior is essential for developing targeted therapies aimed at disrupting their pro-tumorigenic functions [2]

Description

CAFs, a heterogeneous population of stromal cells, are known for their multifaceted functions within the tumor microenvironment. In gastrointestinal cancers, CAFs play pivotal roles in modulating the Extracellular Matrix (ECM), promoting angiogenesis, and facilitating immune evasion. While traditionally considered promoters of tumor growth, recent research has uncovered a nuanced view of CAFs, revealing their dynamic nature and context-dependent functions. In the initial stages of gastrointestinal cancer, CAFs often support tumor growth through the secretion of growth factors, cytokines, and remodeling of the ECM. Their paracrine interactions with cancer cells create a permissive environment for tumorigenesis, fostering cell proliferation and survival. As gastrointestinal tumors progress, CAFs contribute to angiogenesis, promoting the formation of new blood vessels that sustain the growing tumor. Moreover, CAFs actively participate in the metastatic process by facilitating cancer cell invasion and migration through the secretion of pro-migratory factors [3].

Gastrointestinal CAFs exert a profound influence on the immune landscape within the tumor microenvironment. They can modulate immune cell functions, creating an immunosuppressive milieu that shields cancer cells from immune surveillance. This immunomodulatory role poses challenges for immunotherapeutic interventions. In advanced stages of gastrointestinal cancer, CAFs contribute to therapeutic resistance. Their interactions with cancer cells can confer resistance to chemotherapy and targeted therapies, limiting the efficacy of conventional treatment approaches. Understanding the mechanisms behind this resistance is critical for devising strategies to overcome treatment hurdles. The dynamic functions of gastrointestinal CAFs are orchestrated by complex molecular signaling pathways. Tumor-derived factors, including Transforming Growth Factor-Beta (TGF-β), Platelet-Derived Growth Factor (PDGF), and Fibroblast Growth Factor (FGF), play pivotal roles in activating CAFs. Epigenetic modifications and post-translational alterations further contribute to the heterogeneity and plasticity of CAFs, allowing them to adapt to changing tumor conditions [4].

Recent studies have unraveled the heterogeneity within the CAF population, indicating that different subsets of CAFs may have distinct functions. Subpopulations such as myofibroblastic CAFs, inflammatory CAFs, and senescent CAFs exhibit diverse phenotypes and functions in gastrointestinal tumors. Understanding this heterogeneity is crucial for developing targeted therapies that selectively interfere with pro-tumorigenic CAF subsets. Given the evolving understanding of gastrointestinal CAFs, there is growing interest in exploring them as potential therapeutic targets. Strategies aimed at disrupting CAF functions include targeting specific signaling pathways, modulating the tumor immune microenvironment, and developing agents that selectively deplete pro-tumorigenic CAF subsets. Precision medicine approaches tailored to individual patients' CAF profiles hold promise for enhancing treatment outcomes [5].

Conclusion

Despite significant progress in unraveling the roles of gastrointestinal CAFs, several challenges remain. Identifying reliable biomarkers to distinguish different CAF subsets and developing non-invasive imaging techniques to assess CAF activity in vivo are critical areas of ongoing research. Moreover, understanding the crosstalk between CAFs and other components of the tumor microenvironment will provide a more holistic view of their functions. Gastrointestinal CAFs, once considered simple bystanders, have emerged as dynamic orchestrators of the tumor microenvironment, influencing cancer progression and therapeutic responses. The evolving functions of CAFs underscore the need for a nuanced understanding of their roles at different stages of gastrointestinal cancer. Unraveling the molecular mechanisms governing CAF behavior and harnessing this knowledge for targeted therapeutic interventions represent exciting avenues for advancing precision medicine in gastrointestinal cancer treatment. As research progresses, a deeper understanding of CAF heterogeneity and plasticity will guide the development of innovative strategies aimed at disrupting their pro-tumorigenic functions, ultimately improving patient outcomes in gastrointestinal cancer.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Sherchan, Prativa, Zachary D. Travis, Jiping Tang and John H. Zhang. "The potential of Slit2 as a therapeutic target for central nervous system disorders." Exp Opin Ther Target 24 (2020): 805-818.

   Google Scholar, Crossref, Indexed at

2. Li, Peng, Zhiping Lin, Qianzheng Liu and Siyuan Chen, et al. "Enhancer RNA SLIT2 inhibits bone metastasis of breast cancer through regulating P38 MAPK/c-Fos signaling pathway." Front Oncol 11 (2021): 743840.

   Google Scholar, Crossref, Indexed at

3. Kalluri, Raghu. "The biology and function of fibroblasts in cancer." Nat Rev Cancer 16 (2016): 582-598.

   Google Scholar, Crossref, Indexed at

4. Yin, Zeli, Chengyong Dong, Keqiu Jiang and Zhe Xu, et al. "Heterogeneity of cancer-associated fibroblasts and roles in the progression, prognosis, and therapy of hepatocellular carcinoma." J Hematol Oncol 12 (2019): 1-9.

   Google Scholar, Crossref, Indexed at

5. Gascard, Philippe and Thea D. Tlsty. "Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy." Genes Develop 30 (2016): 1002-1019.

   Google Scholar, Crossref, Indexed at